

META HEALTH LIMITED
(Incorporated in the Republic of Singapore)
(Company Registration No. 198804700N)

**RENOUNCEABLE NON-UNDERWRITTEN RIGHTS ISSUE OF UP TO 264,078,029 NEW
ORDINARY SHARES IN THE CAPITAL OF META HEALTH LIMITED (“RIGHTS ISSUE”)**

- **RESULTS OF THE RIGHTS ISSUE**
 - **FINAL NET PROCEEDS FROM THE RIGHTS ISSUE**
-

1. INTRODUCTION

- 1.1. The board of directors (the “**Board**”) of Meta Health Limited (the “**Company**”) refers to the Company’s announcements dated 5 December 2024, 6 January 2025, 9 January 2025, 20 January 2025 and 22 January 2025 (the “**Previous Announcements**”) in relation to the Rights Issue; and (ii) the Company’s offer information statement dated 20 January 2025 in relation to the Rights Issue, which was electronically disseminated by the Company on 20 January 2025 (the “**Offer Information Statement**”).
- 1.2. Unless otherwise defined, all capitalised terms used in this announcement shall bear the same meanings ascribed to them in the Offer Information Statement.

2. RESULTS OF THE RIGHTS ISSUE

2.1. Level of Subscription

Based on the total number of 1,056,312,116 issued Shares (excluding treasury shares and subsidiary holdings) as at the Record Date, a total of 264,078,029 Rights Shares were available for subscription under the Rights Issue.

The Company is pleased to announce that, as at the Closing Date of 7 February 2025 for the Rights Issue, valid acceptances and valid Excess Applications were received for a total of 267,789,484 Rights Shares, representing approximately 101.4% of the 264,078,029 Rights Shares available for subscription under the Rights Issue. Details of the valid acceptances and valid Excess Applications received for the Rights Shares under the Rights Issue are as follows:

	Number of Rights Shares	As a percentage of the total number of Rights Shares available for subscription under the Rights Issue ⁽¹⁾
Valid acceptances	93,262,305	35.3%
Valid Excess Applications	174,527,179	66.1%
Total	267,789,484	101.4%

Note:

(1) Rounded to the nearest decimal place.

Applicants with valid acceptances of their provisional allotments of Rights Shares will be allocated in full for such acceptances.

2.2. Excess Applications

A total of 170,815,724 provisional allotments of Rights Shares (including unsold “nil-paid” provisional allotments of Rights Shares of Foreign Shareholders and fractional entitlements which were disregarded in arriving at the Entitled Shareholders’ provisional allotments of Rights

Shares) which were not validly accepted or subscribed for by the Entitled Shareholders, Renouncees and Purchasers, will be allotted to satisfy the valid Excess Applications for the Rights Shares.

In the allotment of the Excess Rights Shares, preference was given to Shareholders for the rounding of odd lots. Directors and Substantial Shareholders who have control or influence over the Company in connection with the day-to-day affairs of the Company or the terms of the Rights Issue, or have representation (direct or through a nominee) on the Board, ranked last in priority for the rounding of odd lots and allotment of Excess Rights Shares. No Excess Rights Shares will be allotted which would result in a transfer of Controlling Interest in the Company.

2.3. **Allotment and Crediting of Rights Shares**

In the case of Entitled Depositors, Purchasers and their Renouncees with valid acceptances of their provisional allotments of Rights Shares and (if applicable) successful Excess Applications, share certificate(s) representing such number of Rights Shares will be sent to CDP within ten (10) Market Days after the Closing Date and CDP will thereafter credit such number of Rights Shares to their relevant Securities Accounts. CDP will then send to the relevant subscribers **by ordinary post and at their own risk**, to their mailing addresses in Singapore in the records of CDP, a notification letter stating the number of Rights Shares that have been credited to their Securities Accounts. The Rights Shares are expected to be credited to the relevant Shareholders' respective Securities Accounts on or around 17 February 2025.

2.4. **Sale of Nil-Paid Rights of Foreign Shareholders**

None of the 2,428,287 provisional allotments of Rights Shares which would otherwise have been provisionally allotted to Foreign Shareholders have been sold "nil-paid" on the Catalyst during the Rights Trading Period as provided in the Offer Information Statement. The Rights Shares represented by such provisional allotments are utilised to satisfy the Excess Applications, disposed of or dealt with in such manner as the Board may, in their absolute discretion, deem fit in the interests of the Company and no Foreign Shareholder or persons acting to the account or benefit of any such persons shall have any claim whatsoever against the Company, the Directors, the Sponsor, the Manager, CDP, the Share Registrar and/or their respective officers in connection therewith.

3. **REFUND FOR INVALID OR UNSUCCESSFUL ACCEPTANCES AND EXCESS APPLICATIONS AND OF SURPLUS APPLICATION MONIES**

Monies accompanying invalid or unsuccessful acceptances of the provisional allotment of Rights Shares and/or Excess Applications and surplus application monies will be refunded to the relevant Entitled Shareholders, Purchasers and/or Renouncees, without interest or any share of revenue or other benefit arising therefrom within three (3) Market Days after the commencement of trading of the Rights Shares by any one (1) or a combination of the following:

- (a) where the acceptance and/or application had been made through Electronic Application through an ATM of the Participating Bank or an Accepted Electronic Service, by crediting the relevant applicant's bank account with the relevant bank at the relevant applicant's own risk, the receipt by such bank being a good discharge of the Company's, the Manager's and CDP's obligations, if any, thereunder;
- (b) where the acceptance and/or application had been made through the Share Registrar, by means of a crossed cheque drawn in Singapore currency on a bank in Singapore and sent by ordinary post at the relevant applicant's **own risk** to the relevant applicant's mailing address as maintained in the records of the Share Registrar; and/or
- (c) where the acceptance and/or application had been made through CDP, by crediting their designated bank accounts via CDP's Direct Crediting Service or in the case where refunds are to be made to Depository Agents or Member Companies, by means of telegraphic transfer. In the event that an applicant is not subscribed to CDP's Direct Crediting Service, any monies to be returned or refunded will be retained by CDP and

credited to his Cash Ledger and subject to the same terms and conditions as Cash Distributions under CDP's "Terms and Conditions for Operation of Securities Accounts with The Central Depository (Pte) Limited" ("**Member Company**", "**Cash Ledger**" and "**Cash Distributions**" are as defined therein) (such retention by CDP being a good discharge of the obligations of each of the Company and the Manager).

4. FINAL NET PROCEEDS FROM THE RIGHTS ISSUE

- 4.1. On the close of the Rights Issue, based on the aggregate subscription of 264,078,029 Rights Shares, the Company raised approximately S\$1.58 million of gross proceeds from the Rights Issue. After deducting expenses of approximately S\$0.15 million incurred in connection with the Rights Issue, the final net proceeds from the Rights Issue are approximately S\$1.43 million ("**Final Net Proceeds**").

The Final Net Proceeds will be allocated and utilised by the Group as follows, in accordance with the allocation as disclosed in the Offer Information Statement:

Use of Final Net Proceeds	Amount (S\$'000)	Percentage of Final Net Proceeds (%)
Repayment of existing loans	790	55
General corporate and working capital purposes of the Group	640	45
Total	1,430	100

- 4.2. The Company will make periodic announcements on the utilisation of the Final Net Proceeds as and when such proceeds are materially disbursed and whether such disbursements are in accordance with the stated use of proceeds and in accordance with the percentage allocated. The Company will also provide a status report on the use of the Final Net Proceeds in the Company's interim and full year financial results announcement(s) and in the Company's annual report(s) until such time the Final Net Proceeds have been fully utilised. Where the Final Net Proceeds are used for general corporate and working capital purposes, the Company will provide a breakdown with specific details on how the Final Net Proceeds have been applied in the Company's announcements and annual reports. Where there is any material deviation from the stated use of the Final Net Proceeds, the Company will announce the reasons for such deviation.
- 4.3. Pending the deployment of the Final Net Proceeds for the abovementioned purposes, such proceeds may, subject to relevant laws and regulations, be placed as deposits with banks and/or financial institutions, or invested in short-term money market instruments or debt instruments and/or used for any other purposes on a short-term basis as the Board may, in their absolute discretion, deem appropriate in the interests of the Group.

5. ISSUE AND LISTING OF AND QUOTATION FOR THE RIGHTS SHARES

- 5.1. Barring any unforeseen circumstances, the Company expects that 264,078,029 Rights Shares will be allotted and issued on or about 13 February 2025 pursuant to the Rights Issue. The Rights Shares, when allotted and issued, will rank *pari passu* in all respects with the then existing Shares, save for any dividends, rights, allotments or other distributions, the record date for which falls before the date of issue of the Rights Shares.
- 5.2. The Company also expects that the Rights Shares will be listed and quoted on the Catalist on or about 17 February 2025 and trading of such Rights Shares will commence with effect from 9.00 a.m. on 17 February 2025. The Company will make an announcement to inform Shareholders on the date of the listing of and quotation for the Rights Shares on the Catalist in due course.
- 5.3. The Board wishes to take this opportunity to thank Shareholders who have participated in the Rights Issue for their support for the Rights Issue and the Company.

BY ORDER OF THE BOARD

Gwendolin Lee Soo Fern
Company Secretary
12 February 2025

This announcement has been reviewed by the Company's sponsor, ZICO Capital Pte. Ltd. (the "Sponsor").

This announcement has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "SGX-ST") and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms Lim Hui Zheng, ZICO Capital Pte. Ltd. at 77 Robinson Road, #06-03 Robinson 77, Singapore 068896, telephone (65) 6636 4201.